ストックスクリーナーアプリを入手
54.08
2.31%
-1.28
アフターアワーズ：
54.04
-0.04
-0.07%
Akero Therapeutics Inc (AKRO) 最新ニュース
Equities Analysts Issue Forecasts for AKRO FY2029 Earnings - MarketBeat
Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy Sells 5,000 Shares - MarketBeat
UBS Group Issues Positive Forecast for Akero Therapeutics (NASDAQ:AKRO) Stock Price - MarketBeat
Finance Watch: Metsera, Maze Go Public, Bringing 2025 US IPO Total To Three - News & Insights
Akero Therapeutics chief development officer sells shares worth $3.01 million - Investing.com India
Akero Therapeutics chief development officer sells shares worth $3.01 million By Investing.com - Investing.com South Africa
Akero Therapeutics chief development officer sells $2.73 million in stock - Investing.com India
Akero Therapeutics chief development officer sells $2.73 million in stock By Investing.com - Investing.com Canada
Why did Akero (AKRO) stock soar 110% on Monday? - MSN
Akero Therapeutics price target raised to $73 from $56 at Canaccord - MSN
Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 31,250 Shares of Stock - MarketBeat
Akero raised to Buy at Bank of America after liver drug data - MSN
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Yahoo Finance
Akero stock raised to Buy at Bank of America (AKRO:NASDAQ) - Seeking Alpha
Akero Therapeutic prices upsized stock offering of $350M - MSN
Akero Therapeutics (NASDAQ:AKRO) Trading 4.8% Higher After Analyst Upgrade - MarketBeat
Akero Therapeutics senior VP sells $285,150 in stock - MSN
Akero Therapeutics shares soar on positive study results - MSN
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
Akero Therapeutics (NASDAQ:AKRO) Raised to Buy at Bank of America - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Akero Therapeutics, Inc. (AKRO) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Akero Therapeutics CEO Andrew Cheng sells $1.65 million in stock - MSN
Akero Therapeutics senior VP sells $285,150 in stock By Investing.com - Investing.com Australia
Akero Therapeutics' chief scientific officer sells $1.74 million in stock - MSN
Akero Therapeutics Stock Doubles on Liver Data - MSN
Akero Therapeutics announces proposed public offering of common stock - MSN
Akero Therapeutics' chief scientific officer sells $1.74 million in stock By Investing.com - Investing.com Canada
Akero Therapeutics CEO Andrew Cheng sells $1.65 million in stock By Investing.com - Investing.com UK
Jefferies raises Akero Therapeutics price target to $75 - MSN
MASH momentum prompts $250 million raise for 89bio - The Pharma Letter
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH Study - MSN
Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results - MSN
BioAge drops obesity drug; Akero, 89bio cash in on MASH data - BioPharma Dive
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH Study - MSN
Morgan Stanley lifts Akero Therapeutics stock to $96 - MSN
Morgan Stanley Raises Akero Therapeutics (NASDAQ:AKRO) Price Target to $96.00 - MarketBeat
AKRO stock hits 52-week high, soaring to $56.86 - MSN
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - The Manila Times
Akero's Massive $350M Capital Raise Signals Major Development Push in NASH Treatment - StockTitan
Canaccord raises Akero Therapeutics target to $73 - MSN
Akero: Reversal Of Cirrhosis With EFX Is A "First" In F4 MASH Patients (NASDAQ:AKRO) - Seeking Alpha
Akero Therapeutics (NASDAQ:AKRO) Given New $96.00 Price Target at Morgan Stanley - MarketBeat
Some Good MASH/NASH News From Akero Therapeutics (AKRO) - Seeking Alpha
9 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Akero Therapeutics reports breakthrough in MASH cirrhosis study By Investing.com - Investing.com Canada
Akero’s cirrhosis treatment shows promise in Phase IIb study - Yahoo Finance
Akero Therapeutics (NASDAQ:AKRO) Shares Gap Up Following Analyst Upgrade - MarketBeat
Akero Therapeutics succeeds with MASH liver treatment at phase 2 - BioPharma-Reporter.com
Royal Caribbean Cruises Posts Upbeat Earnings, Joins Brighthouse Financial, Invesco, Boeing And Other Big Stocks Moving Higher On Tuesday - Benzinga
Citi raises Akero Therapeutics stock target to $80 on EFX data - MSN
Canaccord raises Akero Therapeutics target to $73 By Investing.com - Investing.com Nigeria
Why Akero Therapeutics Inc. (AKRO) Surged on Monday - Insider Monkey
Citigroup Increases Akero Therapeutics (NASDAQ:AKRO) Price Target to $80.00 - MarketBeat
3.95%
2.39%
大文字化:
|
ボリューム (24 時間):